JACC Journals

09/28/2025

Acoramidis reduced cumulative cardiovascular outcomes in vs placebo, with numerical differences by month 1 and increasing through month 30 (53 events avoided/100 patients). Nearly 1/4 of events occurred in the first 6 months, underscoring the need for timely treatment.

Get the details: https://bit.ly/4gLv5DG

09/27/2025

New case presents a 10-year, single-center case series of 21 CAP cases, highlighting 5 key cases: type III CAP treated with a covered stent complicated by side branch occlusion; calcified perforation complicated by stent thrombosis; distal wire perforation with fatal outcome; chronic total occlusion-related CAP managed with coiling and surgery; and type IV CAP with delayed deterioration.

AbstractBackgroundCoronary artery perforation (CAP) is an uncommon but serious complication of percutaneous coronary intervention, with a mortality rate of 10% to 20%. Its relevance is increasing w...

09/26/2025

Sometimes a single image can transform understanding. This month’s Amara Yad submission reveals the crux of the heart in exquisite detail, a powerful reminder of the beauty and complexity within. https://bit.ly/4pNT09K

09/26/2025

Between 2021-2025, relatively few AHFTC (Advanced Heart Failure/Transplant Cardiology) programs matched the majority of applicants. Applicants prioritize markers of hospital reputation and heart transplant volumes over regional disease burden or geographical considerations. These findings may have multiple implications in an era of declining interest in AHFTC training.

Learn more: https://bit.ly/4nHnWXP

09/25/2025

At , experts unveiled pivotal findings from the 2023 , analyzing cardiovascular disease trends across 204 countries from 1990 to 2023. Explore the full insights here: https://bit.ly/4pxeDe6

Editor-in-Chief Dr. Harlan Krumholz emphasized that the Global Burden of JACC manuscript should be a “compass, not a mirror," in that the data should not just reflect where we are, but guide where we need to focus our efforts.

He also noted: “We have to start thinking differently about how we’re delivering care. I believe AI can make a difference.”

Hosted by JACC, the National Heart, Lung, and Blood Institute (NHLBI), and the Institute for Health Metrics and Evaluation (IHME), this collaboration is shaping the future of global heart health.

09/25/2025

📢 Today in : 3 new methodology statements from the ACC/AHA Joint Committee on Clinical Practice Guidelines:
🔹 Core Principles & Development Process
🔹 Cost/Value Methodology (updated from 2014)
🔹 Guidance for Incorporating FDA Processes

Published alongside Circulation, these companion documents provide the framework to ensure guidelines remain rigorous, transparent & responsive to advances in science, regulation & health care delivery.

🔗 Explore the statements: https://bit.ly/3IE4EDc

09/25/2025

New in : A cross-trial analysis of 3 cardiac amyloidosis trials reveals time-dependent effects of modern disease-modifying therapies on mortality.

Get the details: https://bit.ly/4pH3E1S

09/24/2025

New study from ERCTO (European Registry of Chronic Total Occlusion) shows rising use of drug-coated balloons (DCBs) in chronic total occlusion percutaneous coronary intervention. Findings highlight reduced stent length, lower contrast use, and fewer tamponade events, supporting DCBs as a promising strategy in complex lesions.

AbstractBackgroundDrug-coated balloons (DCBs) are increasingly used in percutaneous coronary intervention (PCI). Their application for chronic total occlusions (CTOs) is a promising option to limit...

09/24/2025

A new report in , published to coincide with a event, highlights the urgent need to prioritize heart health. Cardiovascular diseases (CVD) caused 1 in 3 deaths worldwide as a result of population growth, population aging and exposure to a broad range of risks, including increasing rates of obesity and diabetes.

The updated report shows wide global, regional and national variation in burden, even among countries with similar economies. Researchers estimated burden due to 376 diseases, including CVD, from 1990 to 2023 in 204 countries using all available data and statistical models.

Read the report: https://bit.ly/4nOccCl

Institute for Health Metrics and Evaluation (IHME)

AbstractBackgroundCardiovascular diseases (CVDs) are the leading cause of mortality and are among the foremost causes of disability globally. CVD burden has continued to increase in most countries ...

09/23/2025

Anticoagulation in pulmonary arterial hypertension has long been debated. This nationwide registry + updated meta-analysis provides sobering clarity: no significant survival benefit. Only randomized trials can now settle the score.

Get the details in :

AbstractBackgroundThe role of anticoagulant therapy in the management of pulmonary arterial hypertension (PAH) remains uncertain, as existing epidemiologic studies have produced conflicting results...

09/23/2025

case highlights the role of exercise right heart catheterization in detecting early pulmonary vascular disease and supports vasoreactivity testing to guide therapy. Exercise-induced pulmonary arterial hypertension may be the initial manifestation of autoimmune disease and should be considered in young patients with exertional symptoms and nondiagnostic resting evaluations.

AbstractBackgroundExercise right heart catheterization (RHC) is a valuable diagnostic tool for identifying hemodynamic abnormalities that may not be evident at rest.Case SummaryA 36-year-old woman ...

09/22/2025

Latest study validates IVUS-defined stent expansion criteria, showing that achieving a minimal stent area >5.5 mm² significantly improves 1-year outcomes after PCI, reducing target vessel failure and adverse cardiac events. Read more below. https://bit.ly/3Kh2ZE3